Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study-Reference-Cited by-同舟云学术

Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study

Published:2023-04-27 Issue:1 Volume:34 Page:
ISSN:0953-7104
Container-title:Platelets
language:en
Short-container-title:Platelets

Author:

Mageau Arthur¹,Bonnotte Bernard²,Ebbo Mikael³,Dossier Antoine⁴,Galicier Lionel⁵,Souchaud-Debouverie Odile⁶,Orvain Corentin⁷,Gerfaud-Valentin Mathieu⁸,Gobert Delphine⁹,Riviere Etienne¹⁰,Audia Sylvain²,Mahevas Matthieu¹,Michel Marc¹,Viallard Jean-Francois¹⁰,Godeau Bertrand¹

Affiliation:

1. Centre de référence des cytopénies auto-immunes de l’adulte, Service de Médecine Interne, Hôpital Henri Mondor, APHP, UPEC, Créteil, France

2. Service de Médecine Interne et d’Immunologie Clinique, CHU Dijon-Bourgogne, Dijon, France

3. Département de Médecine Interne, Aix Marseille Univ, APHM, Hôpital de la Timone, Marseille, France

4. Service de Médecine Interne, Hôpital Bichat-Claude Bernard, APHP, Université de Paris, Paris, France

5. Service d’Immunopathologie Clinique, Hôpital Saint-Louis, APHP, Université de Paris, Paris, France

6. Service de Médecine Interne, Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Poitiers, Poitiers, France

7. Service des Maladies du Sang, Centre Hospitalier Universitaire (CHU) d’Angers, Angers, France

8. Service de Médecine Interne, Hôpital de la Croix-Rousse, HCL, Lyon, France

9. Service de Médecine Interne, Hôpital Saint-Antoine, APHP, Université de Paris, Paris, France

10. Service de médecine interne CHU Bordeaux, Université de Bordeaux, Bordeaux, France

Funder

no funding

Publisher

Informa UK Limited

Subject

Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/09537104.2023.2200848

Reference25 articles.

1. American Society of Hematology 2019 guidelines for immune thrombocytopenia

2. HAS. PNDS Purpura thrombopénique immunologique de l’enfant et de l’adulte. Haute Aut Santé . 2017.

3. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients

4. Top drugs and companies by sales in 2018

5. The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of platelet desialylation as a biomarker in primary immune thrombocytopenia: mechanisms and therapeutic perspectives;Frontiers in Immunology;2024-06-24

2. Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 study;The Lancet Regional Health - Western Pacific;2024-06